FABP5抑制剂ART26.12在临床前银屑病模型中显示疗效
本研究评估了口服FABP5抑制剂ART26.12在体外重建人表皮和体内咪喹莫特小鼠银屑病模型中的疗效。体外实验显示ART26.12(3和10 μM)可降低细胞因子、趋化因子及角质形成细胞增殖/分化标志物。体内实验中ART26.12(25 mg/kg每日两次)与TYK2抑制剂BMS-986165 comparable地减轻银屑病样症状,组织病理学改善,蛋白组学与脂质组学提示其通过脂质调控相关通路发挥作用。
要点
- ART26.12在体外降低银屑病相关基因表达并调节角质形成细胞标志物
- 体内与BMS-986165 comparable减轻咪喹莫特诱导的银屑病样症状
- 蛋白组学提示ART26.12可能通过脂质调控影响PPAR、NF-kB和PKC通路
核心结论
- ART26.12可能成为银屑病的潜在治疗药物。
研究设计与样本
- 体外:重建人表皮经IL-17+IL-22+TNF(各3 ng/ml)刺激后,用ART26.12(1、3、10 μM)或Jak1抑制剂(10 μM)处理24小时,检测64个银屑病相关基因。
- 体内:咪喹莫特小鼠模型口服ART26.12(25或100 mg/kg每日两次)或BMS-986165(10 mg/kg每日一次)10天。
主要发现
- ART26.12(3和10 μM)降低细胞因子、趋化因子及角质形成细胞增殖/分化标志物,增加某些抗菌肽。
- ART26.12(25 mg/kg每日两次)与BMS-986165 comparable地在咪喹莫特处理第6天减轻银屑病样症状。
- 组织病理学显示ART26.12减轻角化过度、角化不全、表皮棘层肥厚和炎症浸润。
- 蛋白组学提示ART26.12恢复FLG-2表达,促进表皮分化复合体相关蛋白,调节PPAR、NF-kB和PKC通路。
- 脂质组学显示广泛调节,包括神经酰胺和亚油酸衍生物。
关键数值与推荐
- 体外刺激因子浓度:IL-17、IL-22、TNF各3 ng/ml;ART26.12浓度1、3、10 μM;Jak1抑制剂10 μM;处理24小时。
- 体内给药:ART26.12 25或100 mg/kg每日两次;BMS-986165 10 mg/kg每日一次;给药10天。
临床怎么用
- 临床前数据支持ART26.12作为银屑病潜在口服治疗药物进一步开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FABP5 is upregulated in psoriasis. This study assessed the efficacy of the potent, selective, and orally active FABP5 inhibitor ART26.12 in preclinical psoriasis models. In vitro, reconstructed human epidermis was stimulated with cytokines (IL-17 + IL-22 + TNF at 3 ng/ml each) and treated with ART26.12 (1, 3, or 10 μM) or Jak1 inhibitor (10 μM) for 24 hours; after which, 64 psoriasis-related genes were measured. ART26.12 (3 and 10 μM) treatment reduced cytokines, chemokines, and markers of keratinocyte proliferation/differentiation and increased certain antimicrobial peptides. In vivo, ART26.12 (25 or 100 mg/kg twice a day) or BMS-986165 (TYK2 inhibitor; 10 mg/kg once a day) was given orally for 10 days in the imiquimod mouse model. Imiquimod increased psoriasis-like symptoms. ART26.12 (25 mg/kg twice a day) and BMS-986165 comparably reduced psoriasis-like symptoms by day 6 of imiquimod treatment. Histopathology showed that ART26.12 reduced symptom severity, for example, hyperkeratosis, parakeratosis, epidermal acanthosis, and inflammatory infiltrates. Proteomic analysis indicated that ART26.12 rescued the expression of FLG-2; promoted epidermal differentiation complex-associated proteins; and modulated peroxisome proliferator-activated receptor, NF-kB, and protein kinase C pathways likely downstream of lipid modulation. Lipidomic analysis showed widespread modulation, including ceramides and linoleic acid derivatives. These data suggest that ART26.12 may be a potential psoriasis treatment.
引用
- Warren WG, Osborn M, Yates A, et al. ART26.12, an FABP5 Inhibitor, Shows Efficacy in Preclinical Psoriasis Models. J Invest Dermatol. 2025. PMID: 40210114. doi:10.1016/j.jid.2025.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。